Some doctors told him he'd live with the disease forever, but Khaled Alsheebani never stopped believing treatments would ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...